Atai Life Sciences (NASDAQ: ATAI) is one of the. On June 6, analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Atai Life Sciences (NASDAQ:ATAI), retaining the price target of $6.00.

In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab.Patients who underwent ...

As an extreme heat watch goes into effect concurrent with the start of the summer season, a local lake has reopened to the public.

The rise in popularity of shadow work and trauma healing, concurrent with the urgent national conversations about public land ...

At its event this week, Pure Storage unveiled FlashBlade//EXA, built to power AI and HPC workloads with 10TB/s read speeds, ...

Adults with treatment-resistant depression who received IV ketamine showed improvement in sadness-related symptoms ...

Among the latest teams to join the platform is Alden Capital Management of Bellevue, WA ($390 million AUM), which cited Concurrent's advisor-first culture, flexible architecture, and integrated ...

American College of Education Partnered With More Than 2,500 Organizations to Create Solutions That Provide Top-Quality ...